Brought to you by 
Eli Lilly licenses 3-D technology from Structural GenomiX
14 May 2003
Executive Summary
Structural GenomiX will apply its gene-to-structure technology to some key Eli Lilly drug targets and also set up a copy of its system in a high-throughput structural biology facility where Lilly can use it long term in its internal programs for lead generation and optimization.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com